Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
F Ronchetto, V Musso
OBJECTIVE: To investigate the frequency of cardiac arrhythmias, conduction disturbances and other electrocardiographic abnormalities in elderly in-patients without clinical evidence of heart disease, and in relation to different age groups. DESIGN: Retrospective analysis of the standard 12-lead electrocardiogram recordings. METHODS: Resting electrocardiograms of 595 in-patients aged 65 years and older, without cardiac diagnoses, over a period of one year were examined...
September 1998: Recenti Progressi in Medicina
#2
REVIEW
Pablo Díez-Villanueva, Fernando Alfonso
Atrial fibrillation (AF) is the most common arrhythmia in elderly population, with age being one of the most important factors involved in its pathogenesis. Conduction disturbances may be present on the surface electrocardiogram before AF onset in some patients. Once this arrhythmia is diagnosed, antithrombotic therapy is mandatory in most cases, as this is the only treatment that has demonstrated to improve survival. Age increases both the risk of thromboembolic and bleeding complications, while benefits from anticoagulant therapy outweigh that from bleeding in most scenarios, also in very elderly patients...
January 2019: Journal of Geriatric Cardiology: JGC
#3
JOURNAL ARTICLE
Susanne C de Ruiter, Johan F H Wold, Tjeerd Germans, Jaap H Ruiter, René W M M Jansen
AIMS: To assess the diagnostic outcomes of a multidisciplinary pathway for elderly syncope patients. METHODS AND RESULTS: Observational cohort study at a Fall and Syncope Clinic, including consecutive syncope patients aged ≥65 years between 2011 and 2014. Measurements: The sort, number, and accuracy of diagnoses resulting in syncope. Secondary outcomes: reliability of the medical history and the number of electrocardiogram (ECG) abnormalities. The 117 included patients (72% females) had a mean age of 80 ± 6...
May 1, 2018: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
#4
REVIEW
Bostjan Berlot, Chiara Bucciarelli-Ducci, Alberto Palazzuoli, Paolo Marino
Heart failure (HF) with either reduced or preserved ejection fraction is an increasingly prevalent condition. Cardiac imaging plays a central role in trying to identify the underlying cause of the underlying systolic and diastolic dysfunction, as the imaging findings have implications for patient's management and individualised treatment. The imaging modalities used more frequently in patients with heart failure in clinical routine are echocardiography and cardiac magnetic resonance. Both techniques keep some strengths and weakness due to their spatial and temporal resolution...
January 2020: Heart Failure Reviews
#5
REVIEW
Marco Giuseppe Del Buono, Giulia Iannaccone, Roberto Scacciavillani, Salvatore Carbone, Massimiliano Camilli, Giampaolo Niccoli, Barry A Borlaug, Carl J Lavie, Ross Arena, Filippo Crea, Antonio Abbate
Over the last several decades, clinicians and clinical scientists have had growing interest in heart failure (HF) diagnosis and treatment. While HF with reduced ejection fraction (EF) is a well-known clinical entity with several therapeutic strategies proven to be successful, HF with preserved ejection fraction is a more heterogenous syndrome with a prevalence that has increased in the last two decades, without effective therapeutic strategies. Great strides have been made in the detection of predisposing risk factors and pathological mechanisms; however, pharmacological therapies have shown to be ineffective in reducing cardiovascular mortality in the HF with preserved EF (HFpEF) population, opening the way to the necessity of developing new precision medicine based approaches...
September 2020: Progress in Cardiovascular Diseases
#6
REVIEW
Melissa A Lyle, Frank V Brozovich
Patients with heart failure are commonly divided into those with reduced ejection fraction (EF<40%) and those with preserved ejection fraction (HFpEF; EF>50%). For heart failure with reduced EF, a number of therapies have been found to improve patient morbidity and mortality, and treatment is guideline based. However for patients with HFpEF, no treatment has been found to have clinical benefit. To objectively assess treatments for HFpEF, a comprehensive PubMed literature search was performed using the terms HFpEF, heart failure, smooth muscle, myosin, myosin phosphatase, and PKG (up to December 31, 2017), with an unbiased focus on pathophysiology, cell signaling, and therapy...
September 2018: Mayo Clinic Proceedings
#7
REVIEW
Sanjiv J Shah, Dalane W Kitzman, Barry A Borlaug, Loek van Heerebeek, Michael R Zile, David A Kass, Walter J Paulus
Heart failure (HF) with preserved ejection fraction (EF; HFpEF) accounts for 50% of HF cases, and its prevalence relative to HF with reduced EF continues to rise. In contrast to HF with reduced EF, large trials testing neurohumoral inhibition in HFpEF failed to reach a positive outcome. This failure was recently attributed to distinct systemic and myocardial signaling in HFpEF and to diversity of HFpEF phenotypes. In this review, an HFpEF treatment strategy is proposed that addresses HFpEF-specific signaling and phenotypic diversity...
July 5, 2016: Circulation
#8
REVIEW
Maria G Crespo-Leiro, Marco Metra, Lars H Lund, Davor Milicic, Maria Rosa Costanzo, Gerasimos Filippatos, Finn Gustafsson, Steven Tsui, Eduardo Barge-Caballero, Nicolaas De Jonge, Maria Frigerio, Righab Hamdan, Tal Hasin, Martin Hülsmann, Sanem Nalbantgil, Luciano Potena, Johann Bauersachs, Aggeliki Gkouziouta, Arjang Ruhparwar, Arsen D Ristic, Ewa Straburzynska-Migaj, Theresa McDonagh, Petar Seferovic, Frank Ruschitzka
This article updates the Heart Failure Association of the European Society of Cardiology (ESC) 2007 classification of advanced heart failure and describes new diagnostic and treatment options for these patients. Recognizing the patient with advanced heart failure is critical to facilitate timely referral to advanced heart failure centres. Unplanned visits for heart failure decompensation, malignant arrhythmias, co-morbidities, and the 2016 ESC guidelines criteria for the diagnosis of heart failure with preserved ejection fraction are included in this updated definition...
November 2018: European Journal of Heart Failure
#9
REVIEW
Véronique L Roger
Heart failure (HF) has been singled out as an epidemic and is a staggering clinical and public health problem, associated with significant mortality, morbidity, and healthcare expenditures, particularly among those aged ≥ 65 years. The case mix of HF is changing over time with a growing proportion of cases presenting with preserved ejection fraction for which there is no specific treatment. Despite progress in reducing HF-related mortality, hospitalizations for HF remain frequent and rates of readmissions continue to rise...
August 30, 2013: Circulation Research
#10
REVIEW
Patrick Rossignol, Adrian F Hernandez, Scott D Solomon, Faiez Zannad
Heart failure is the most common cardiovascular reason for hospital admission for people older than 60 years of age. Few areas in medicine have progressed as remarkably as heart failure treatment over the past three decades. However, progress has been consistent only for chronic heart failure with reduced ejection fraction. In acutely decompensated heart failure and heart failure with preserved ejection fraction, none of the treatments tested to date have been definitively proven to improve survival. Delaying or preventing heart failure has become increasingly important in patients who are prone to heart failure...
March 9, 2019: Lancet
#11
REVIEW
Joanna Osmanska, Pardeep S Jhund
The foundation of the treatment of heart failure with reduced ejection fraction is a number of pharmacotherapies shown to reduce morbidity and mortality in large randomised multinational clinical trials. These include angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists, and more recently, a combined angiotensin receptor blocker neprilysin inhibitor, sacubitril/valsartan. In select cases, digoxin, ivabradine and hydralazine with isosorbide dinitrate have a role to play in the treatment of heart failure with reduced ejection fraction...
February 2019: Drugs & Aging
#12
JOURNAL ARTICLE
John J V McMurray, Stamatis Adamopoulos, Stefan D Anker, Angelo Auricchio, Michael Böhm, Kenneth Dickstein, Volkmar Falk, Gerasimos Filippatos, Cândida Fonseca, Miguel Angel Gomez-Sanchez, Tiny Jaarsma, Lars Køber, Gregory Y H Lip, Aldo Pietro Maggioni, Alexander Parkhomenko, Burkert M Pieske, Bogdan A Popescu, Per K Rønnevik, Frans H Rutten, Juerg Schwitter, Petar Seferovic, Janina Stepinska, Pedro T Trindade, Adriaan A Voors, Faiez Zannad, Andreas Zeiher, Jeroen J Bax, Helmut Baumgartner, Claudio Ceconi, Veronica Dean, Christi Deaton, Robert Fagard, Christian Funck-Brentano, David Hasdai, Arno Hoes, Paulus Kirchhof, Juhani Knuuti, Philippe Kolh, Theresa McDonagh, Cyril Moulin, Bogdan A Popescu, Zeljko Reiner, Udo Sechtem, Per Anton Sirnes, Michal Tendera, Adam Torbicki, Alec Vahanian, Stephan Windecker, Theresa McDonagh, Udo Sechtem, Luis Almenar Bonet, Panayiotis Avraamides, Hisham A Ben Lamin, Michele Brignole, Antonio Coca, Peter Cowburn, Henry Dargie, Perry Elliott, Frank Arnold Flachskampf, Guido Francesco Guida, Suzanna Hardman, Bernard Iung, Bela Merkely, Christian Mueller, John N Nanas, Olav Wendelboe Nielsen, Stein Orn, John T Parissis, Piotr Ponikowski
No abstract text is available yet for this article.
August 2012: European Journal of Heart Failure
#13
REVIEW
Bharathi Upadhya, Barbara Pisani, Dalane W Kitzman
The majority of older adults who develop heart failure (HF), particularly older women, have a preserved left ventricular ejection fraction (HFpEF). The prevalence of this syndrome is increasing, and the prognosis is not improving, unlike that of HF with reduced ejection fraction (HFrEF). Individuals with HFpEF have severe symptoms of effort intolerance, poor quality of life, frequent hospitalizations, and greater likelihood of death. Despite the importance of HFpEF, there are numerous major gaps in our understanding of its pathophysiology and management...
November 2017: Journal of the American Geriatrics Society
#14
REVIEW
Martin Bødtker Mortensen, Erling Falk
The burden of atherosclerotic cardiovascular disease (ASCVD) in high-income countries is mostly borne by the elderly. With increasing life expectancy, clear guidance on sensible use of statin therapy to prevent a first and potentially devastating ASCVD event is critically important to ensure a healthy aging population. Since 2013, 5 major North American and European guidelines on statin use in primary prevention of ASCVD have been released by the American College of Cardiology/American Heart Association, the UK National Institute for Health and Care Excellence, the Canadian Cardiovascular Society, U...
January 2, 2018: Journal of the American College of Cardiology
#15
REVIEW
David H Ellison, G Michael Felker
New England Journal of Medicine, Volume 377, Issue 20, Page 1964-1975, November 2017.
November 16, 2017: New England Journal of Medicine
#16
REVIEW
Seyed Mehrdad Hamrahian
Hypertension is the leading factor in the global burden of disease. It is the predominant modifiable risk factor for stroke, heart disease, and kidney failure. Chronic kidney disease (CKD) is both a common cause and sequel of uncontrolled hypertension. The pathophysiology of CKD-associated hypertension is complex and multi-factorial. This paper reviews the key pathogenic mechanisms of CKD-associated hypertension, the importance of standardized blood pressure (BP) measurement in establishing the diagnosis and management plus the significance of ambulatory BP monitoring for assessment of diurnal BP variation commonly seen in CKD...
May 2017: Current Hypertension Reports
#17
REVIEW
Nikesh Parekh, Amy Page, Khalid Ali, Kevin Davies, Chakravarthi Rajkumar
Hypertension is the leading cause of cardiovascular (CV) morbidity and mortality in adults over the age of 65. The first part of this paper is an overview, summarizing the current guidelines on the pharmacological management of hypertension in older adults in Europe and the USA, and evidence from key trials that contributed to the guidelines. In the second part of the paper, we will discuss the major challenges of managing hypertension in the context of multimorbidity, including frailty, orthostatic hypotension (OH), falls and cognitive impairment that are associated with ageing...
April 2017: Therapeutic Advances in Drug Safety
#18
JOURNAL ARTICLE
Giovanni Corrao, Federico Rea, Matteo Monzio Compagnoni, Luca Merlino, Giuseppe Mancia
OBJECTIVE: To assess whether in individuals aged 85 years or older, adherence to antihypertensive drugs is accompanied by a reduced risk of cardiovascular events. METHODS: A nested case-control study was carried out on a cohort of patients aged 85 years or older, who were newly treated with antihypertensive drugs between 2007 and 2009, using the database available for all citizens (about 10 million) of Lombardy (Italy). Cases were the cohort members who experienced death or hospital discharge for stroke, myocardial infarction (MI) or heart failure from the initial prescription until 2012...
July 2017: Journal of Hypertension
#19
COMPARATIVE STUDY
Hugo González-Saldivar, Carlos Rodriguez-Pascual, Gonzalo de la Morena, Covadonga Fernández-Golfín, Carmen Amorós, Mario Baquero Alonso, Luis Martínez Dolz, Albert Ariza Solé, Gabriela Guzmán-Martínez, Juan José Gómez-Doblas, Antonio Arribas Jiménez, María Eugenia Fuentes, Laura Galian Gay, Martin Ruiz Ortiz, Pablo Avanzas, Emad Abu-Assi, Tomás Ripoll-Vera, Oscar Díaz-Castro, Eduardo P Osinalde, Manuel Martínez-Sellés
The factors that influence decision making in severe aortic stenosis (AS) are unknown. Our aim was to assess, in patients with severe AS, the determinants of management and prognosis in a multicenter registry that enrolled all consecutive adults with severe AS during a 1-month period. One-year follow-up was obtained in all patients and included vital status and aortic valve intervention (aortic valve replacement [AVR] and transcatheter aortic valve implantation [TAVI]). A total of 726 patients were included, mean age was 77...
July 15, 2016: American Journal of Cardiology
#20
REVIEW
F A Flachskampf, W G Daniel
Aortic valve stenosis is the most frequent reason for prosthetic valve replacement in adults. Its incidence increases with age. Development of the most frequent form, degenerative-calcific aortic stenosis, is related to atherosclerotic risk factors. The narrowing of the aortic valve orifice leads to creation of a systolic pressure drop, the gradient, between left ventricle and ascending aorta. The pressure overload from aortic stenosis causes concentric left ventricular hypertrophy and later heart failure. Typical symptoms of severe aortic stenosis include dyspnea, angina, and dizziness or syncope...
November 2004: Der Internist
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
